ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1407

Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis

Peter Taylor1, Janet Pope 2, Kei Ikeda 3, Xiang Zhang 4, Bochao Jia 4, Hong Zhang 5, Amanda Quebe 4, Yun-Fei Chen 4, Carol Gaich 4, Thorsten Holzkaemper 4, Anabela Cardoso 4 and Anthony Sebba 6, 1University of Oxford, Oxford, United Kingdom, 2Western University, London, ON, Canada, 3Chiba University Hospital, Chiba, Japan, 4Eli Lilly and Company, Indianapolis, IN, 5TechData Services, King of Prussia, PA, 6University of South Florida, Palm Harbor, FL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Adalimumab, baricitinib, Disease Activity and pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Treatments Poster II: Established Treatments

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In Phase 3 trial, RA-BEAM, baricitinib (BARI), a JAK1/JAK2 inhibitor, was associated with significant clinical improvements vs. placebo (PBO) and adalimumab (ADA) in RA patients.1 Although BARI and ADA had similar improvement in swollen joint count, BARI demonstrated statistically significantly greater pain improvement. While pain is a generic feature of inflammation, not all pain in RA is due to inflammation, and the contribution of different pathways to pain is unclear. In this post hoc analysis, we assessed the relationship between pain improvement and disease activity and evaluated whether BARI provided additional pain improvement vs. PBO and ADA across levels of disease activity.

Methods: 1,305 patients on stable background MTX were randomized 3:2:3 to and treated with PBO, 40 mg subcutaneous ADA every other week, or daily, oral 4 mg BARI. Pain was assessed with a 0-100 mm visual analog scale (VAS); pain improvement from baseline to Week 12 was grouped by ≤30%, >30% to ≤50%, >50% to ≤70%, and >70%2. Disease activity was measured with the Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), Disease Activity Score for 28 joints (DAS28) with C-reactive protein (CRP), and DAS28 with erythrocyte sedimentation rate (ESR). To evaluate change in pain with disease activity, regression was used with continuous change in pain VAS score from baseline to Week 12 as the outcome and continuous CDAI/SDAI/DAS28-CRP/DAS28-ESR values, treatment, and the interaction term between treatment and disease activity as explanatory variables. Last observation carried forward was used to impute missing values. Pain VAS change at Week 12 was estimated from regression for all treatments if patients achieved remission (REM)/low disease activity (LDA)/moderate disease activity (MDA) as defined by the corresponding clinical measure. Analyses were not adjusted for multiplicity. Data visualization with the percentage of pain VAS improvement vs. disease activity was created to examine pain improvement with treatment over time.

Results: With CDAI, 91% of patients had high disease activity and 9% had MDA across all treatments at baseline. At Week 12, the percentage of patients who achieved REM with PBO, ADA, and BARI, respectively, were 2%, 7%, 8%; for LDA: 15%, 27%, 33%; for MDA: 33%, 40%, 38%.3 At all CDAI values, the estimated change in pain VAS for BARI was greater vs. PBO and ADA (Figure 1); the BARI line is below lines for PBO and ADA across the CDAI range. Similar trends were observed with other disease activity measures (Table). Figure 2 shows the percentage of patients with ≤30%, >30% to ≤50%, >50% to ≤70%, and >70% pain improvement from baseline at Week 12 by disease activity.  BARI demonstrated greater pain improvement vs. ADA and PBO in all disease activity categories.  With CDAI/SDAI, greater differentiation between BARI and ADA was observed as CDAI/SDAI values increased.

Conclusion: BARI provided additional pain improvement vs. PBO and ADA when disease activity was controlled and across all levels of disease activity, as measured by CDAI, SDAI, DAS28-CRP, or DAS28-ESR at Week 12.
References: 1. Taylor, NEJM, 2017; 2. http://www.immpact.org/; 3. Nash ACR abstract 2017

Figure 1. Estimated change in pain VAS by CDAI values at Week 12

Table. Estimated change from baseline in pain VAS at Week 12 by disease activity thresholds, as measured by CDAI, SDAI, DAS28-CRP, and DAS28-ESR

Figure 2. Distribution in percentage improvement from baseline pain VAS to Week 12 by treatment and disease activity -CDAI-


Disclosure: P. Taylor, AbbVie, 5, Abbvie, 5, Biogen, 5, Celgene, 2, 5, Eli Lilly and Company, 2, 5, Fresenius, 5, Fresenius SE & Co, 5, Fresnius, 5, Galapagos, 2, 5, Gilead, 5, GlaxoSmithKline, 5, Janssen, 2, 5, Lilly, 2, 5, Nordic Pharma, 5, NORDIC Pharma, 5, Pfizer, 5, Pfizer Inc, 5, Roche, 5, Sanofi, 5, UCB, 5; J. Pope, AbbVie, 5, Abbvie, 5, Actelion, 5, Actellion, 5, Amgen, 2, 5, AstraZeneca, 2, Astra-Zeneca, 2, Bayer, 2, 5, BMS, 2, 5, Eicos Sciences, 5, Eli Lilly & Company, 5, Eli Lilly and Company, 5, EMERALD, 5, Emerald, 5, Genzyme, 5, Janssen, 5, Lilly, 5, Merck, 2, 5, Novartis, 5, Pfizer, 2, 5, Roche, 2, 5, Sandoz, 5, Sanofi, 5, Seattle Genetics, 2, UCB, 2, 5, 8; K. Ikeda, Abbvie Japan, 8, AbbVie Japan, 8, Bristol-Myers Squibb Japan, 8, Mitsubishi Tanabe Pharma, 2, Novartis Japan, 8; X. Zhang, Eli Lilly and Company, 1, 3; B. Jia, Eli Lilly and Company, 1, 3; H. Zhang, Eli Lilly and Company, 2; A. Quebe, Eli Lilly & Company, 3, 4, Eli Lilly and Company, 1, 3; Y. Chen, Eli Lilly and Company, 1, 3; C. Gaich, Eli Lilly & Company, 3, 4, Eli Lilly and Company, 1, 3, 4; T. Holzkaemper, Eli Lilly and Company, 1, 3; A. Cardoso, Eli Lilly and Company, 1, 3; A. Sebba, Eli Lilly and Company, 8, Genentech, 8, Sanofi, 8, Regeneron, 8, Gilead, 8.

To cite this abstract in AMA style:

Taylor P, Pope J, Ikeda K, Zhang X, Jia B, Zhang H, Quebe A, Chen Y, Gaich C, Holzkaemper T, Cardoso A, Sebba A. Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/baricitinib-provides-better-pain-relief-across-all-disease-activity-levels-compared-with-placebo-and-adalimumab-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baricitinib-provides-better-pain-relief-across-all-disease-activity-levels-compared-with-placebo-and-adalimumab-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology